Candidate gene resequencing to identify rare, pedigree-specific variants influencing healthy aging phenotypes in the long life family study by Druley, TE et al.
RESEARCH ARTICLE Open Access
Candidate gene resequencing to identify
rare, pedigree-specific variants influencing
healthy aging phenotypes in the long life
family study
Todd E. Druley1,2, Lihua Wang1,3, Shiow J. Lin1,3, Joseph H. Lee4,5,6, Qunyuan Zhang1,3, E. Warwick Daw1,3,
Haley J. Abel1,3, Sara E. Chasnoff1,2, Enrique I. Ramos1,2, Benjamin T. Levinson1,2, Bharat Thyagarajan7,
Anne B. Newman8, Kaare Christensen9, Richard Mayeux10 and Michael A. Province1,3*
Abstract
Background: The Long Life Family Study (LLFS) is an international study to identify the genetic components of
various healthy aging phenotypes. We hypothesized that pedigree-specific rare variants at longevity-associated
genes could have a similar functional impact on healthy phenotypes.
Methods: We performed custom hybridization capture sequencing to identify the functional variants in 464
candidate genes for longevity or the major diseases of aging in 615 pedigrees (4,953 individuals) from the LLFS,
using a multiplexed, custom hybridization capture. Variants were analyzed individually or as a group across an
entire gene for association to aging phenotypes using family based tests.
Results: We found significant associations to three genes and nine single variants. Most notably, we found a novel
variant significantly associated with exceptional survival in the 3’ UTR OBFC1 in 13 individuals from six pedigrees.
OBFC1 (chromosome 10) is involved in telomere maintenance, and falls within a linkage peak recently reported
from an analysis of telomere length in LLFS families. Two different algorithms for single gene associations identified
three genes with an enrichment of variation that was significantly associated with three phenotypes (GSK3B with
the Healthy Aging Index, NOTCH1 with diastolic blood pressure and TP53 with serum HDL).
Conclusions: Sequencing analysis of family-based associations for age-related phenotypes can identify rare or
novel variants.
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Background
According to United Nations World Population Prospects
2012 revision (http://esa.un.org/unpd/wpp/Documenta
tion/pdf/WPP2012_HIGHLIGHTS.pdf), the worldwide
average human lifespan was 71 years (68.5 years for males
and 73.5 years for females) over the period 2010–2013. At
least 25 % of human lifespan is dictated by genetic factors,
most of which is unknown [1]. Currently, most human
longevity and healthy aging related variants identified
through genome wide association study (GWAS) are ei-
ther intergenic or intronic with weak effects, and there is
little characterization of coding variants that may influ-
ence human lifespan. For instance, common variants in
multiple genes such as apolipoprotein E (APOE) [2–5],
Forkhead Box O1 (FOXO1) [6], Forkhead Box O3
(FOXO3) [7], Insulin-Like Growth Factor 1 Receptor
(IGF-1R) [6, 8] and Translocase of Outer Mitochondrial
Membrane 40 Homolog (TOMM40) [9] have all been as-
sociated with human lifespan. However, lifespan is a highly
complex trait and healthy aging is controlled and
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influenced by variety of environmental factors and individ-
ual phenotypes [10]. Leukocyte telomere length, Body
Mass Index (BMI), blood pressure, serum lipids, blood
glucose, cognitive function, onset of type 2 diabetes,
heart disease, cancer, and stroke are a few phenotypes
associated with aging, and we hypothesized that
pedigree-specific coding variants associated with these
traits would identify additional genes or pathways im-
portant for regulating human lifespan. While non-
coding variants may have significant gene or epigenetic
regulatory effects, exonic variants would be expected to
exert larger effects on gene function and might there-
fore explain a larger fraction of the variance in these
complex aging phenotypes.
Thus, we expect families clustered for long-lived
healthy members [11, 12] to be enriched for genetic
variants that will promote healthy and/or prolonged
aging. To identify new, rare, heritable variants that are
associated with multiple healthy aging phenotypes, we
performed custom hybridization capture sequencing
of 464 healthy aging related candidate genes in Phase
1 of the Long Life Family Study (LLFS). We then per-
formed association analyses of both rare (<1 % minor
allele frequency) and common variants against mul-
tiple aging-related phenotypes including survival,
leukocyte telomere length, healthy aging index [13],
BMI, blood pressure, blood lipid levels, blood glucose
level, cognitive function, onset of type 2 diabetes,
heart disease, cancer, and stroke.
Methods
Subjects
The LLFS [11], a multi-center family-based cohort
study, enrolled 4,953 individuals from 539 families
clustered for exceptional survival to identify environ-
mental and genetic factors that account for the long
healthy lives in these families. Phase 1 of the LLFS was
conducted between 2006 and 2009. All participants
provided written informed consent prior to inclusion
in the study. The four recruitment centers include
Boston University Medical Center, Columbia Univer-
sity Medical Center, University of Pittsburgh, and Uni-
versity of Southern Denmark. Using the Family
Longevity Selection Score (FLoSS) [14], a score gener-
ated according to birth-year cohort survival probabil-
ities of the proband and siblings, probands and their
families with FLoSS score of 7 or higher, at least one
living sibling, and at least one living offspring (mini-
mum family size of 3), who were able to give informed
consent and willing to participate were recruited. The
spouses were enrolled as controls for this study. The
characteristics of the LLFS population by generation
and by gender are listed in Additional file 1: Table S1
and S2, respectively.
Phenotype measurements
In this study, human lifespan and phenotypic traits re-
lated to healthy aging including survival, leukocyte telo-
mere length, BMI, blood pressure, blood lipid levels,
blood glucose and insulin levels, cognitive function,
healthy aging index, as well as the ages of onset of
stroke, coronary heart disease, congestive heart failure,
cancer, and type 2 diabetes mellitus, were investigated.
Survival and mortality-weighted healthy aging index
The lifespan in LLFS was estimated as the duration of
survival free of death from any cause or from any one of
a specified list of diseases including cardiovascular dis-
ease, congestive heart failure, cancer, stroke, and Type 2
diabetes. The LLFS proband generation, including pro-
bands and full and half siblings (n = 810), was used for
identifying variants related with survival.
Healthy aging was established by the lack of disease
and clinical test values indicating normal function of
various biological systems. To increase the probability
of identifying healthy aging-related genetic variants,
which might influence one or more components of
these biological systems, Sanders et al. proposed the
Healthy Aging Index (HAI) as a subphenotype of lon-
gevity [13]. Using approximate age-adjusted tertiles for
systolic blood pressure, pulmonary vital capacity, cre-
atinine, fasting glucose, and Modified Mini-Mental Sta-
tus Examination score, each individual is scored 0, 1, or
2 for each trait. The HAI is then calculated from the
sum of these scores in a range from 0 (healthy) to 10
(unhealthy). The mortality-weighted HAI is generated
from the sum of the mortality-weighted scores of the
five components listed above. The weights are based on
the regression coefficients from the Cox proportional
hazards model for the effect of each component on sur-
vival and are 0.17085 for systolic blood pressure,
0.38386 for forced vital capacity, 0.42873 for MMSE
points, 0.13397 for serum creatinine, and 0.23880 for
serum fasting glucose.
Glycated hemoglobin (HbA1c), Blood Glucose and Insulin
Levels, Leukocyte Telomere Length, Blood Lipid Levels
Including Total Cholesterol, HDL Cholesterol, LDL
Cholesterol and Triglyceride, BMI, Blood Pressure,
Cognitive Function, Stroke, Coronary Heart Disease,
Congestive Heart Failure, Cancer, Type 2 Diabetes
We looked for any possible association between our can-
didate genes related to healthy aging and various aging
phenotypes including HbA1c, blood glucose and insulin
levels, leukocyte telomere length, blood lipid levels in-
cluding total cholesterol, HDL cholesterol, LDL choles-
terol and triglyceride, BMI, blood pressure, cognitive
function, stroke, coronary heart disease, congestive heart
failure, cancer, and type 2 diabetes.
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As described previously [15], blood samples were col-
lected between 2006 and 2009, and HbA1c was measured
using identical ion exchange-based high performance liquid
chromatography with the Tosoh 2.2 Plus and after 2007
with the Tosch G7 Glycohemoglobin Analyzer (Tosoh
Medics, San Francisco, CA 94080) at the Advanced
Research and Diagnostics Laboratory, University of
Minnesota. Fasting glucose was measured after an 8-h
fast in serum by the Roche hexokinase method (Roche
Diagnostics, Indianapolis, IN 46250) on a Roche Modular
P Chemistry Analyzer (Roche Diagnostics Corporation).
Fasting insulin was measured after an 8-h fast in serum
on a Roche Elecsys 2010 Analyzer (Roche Diagnostics
Corporation) using a sandwich immunoassay method
(Roche Diagnostics, Indianapolis, IN 46250). Assays of
average leukocyte telomere length were described by Lee
et al. [16]. Briefly, Telomeres (T) and beta-globin control
(S) were amplified using real-time PCR of 95 °C for
10 min denaturation, 34 cycles of 95 °C for 15 s and 55 °C
for 120 s performed on the CFX384 thermocycler (BioRad,
Richmond, CA). The leukocyte telomere length was
calculated from T/S ratio using the linear regression for-
mula of bp = (1,585 ∗ T/S ratio) + 3582. Fasting total choles-
terol was measured after an 8-h fast in serum using a
cholesterol oxidase method (Roche Diagnostics, Indianapolis,
IN 46250) on a Roche Modular P Chemistry Analyzer.
Fasting HDL-cholesterol was measured after an 8-h fast
directly in serum using the Roche HDL-Cholesterol 3rd
generation direct method (Roche Diagnostics, Indianapolis,
IN 46250) on a Roche Modular P Chemistry Analyzer.
Fasting triglycerides were measured after an 8-h fast in
serum using Triglyceride GB reagent (Roche Diagnos-
tics, Indianapolis, IN 46250) on a Roche Modular P
Chemistry Analyzer. LDL-cholesterol was calculated by
the Friedewald equation using the measured results for
total cholesterol, HDL-cholesterol, and triglycerides.
This equation (LDL-cholesterol = total cholesterol –
HDL – (triglycerides/5)) can be used to calculate LDL-
cholesterol when triglycerides are less than 400 mg/dL.
The corrected values for triglyceride and LDL choles-
terol was calculated for individuals taking lipid lower-
ing medications [17]. BMI was calculated as weight
(kg)/height (m)2. Sitting systolic and diastolic blood
pressure was obtained by the average of three measures
using an automated blood pressure machine (BP-tru
BPM 300, VMS MedTech, Coquitlam, Canada). Pulse
Pressure was calculated as systolic blood pressure
minus diastolic blood pressure. These results were cor-
rected for individuals taking blood pressure modifying
medication as previously published [18]. General cogni-
tive function including arithmetic, memory, and orien-
tation was assessed using the mini-mental state
examination (MMSE) or Folstein test [19]. Stroke or
cerebrovascular accident includes self-reported stroke,
transient ischemic attack (TIA), or mini-stroke. Coronary
heart disease was defined as self-reported myocardial in-
farction, heart attack, coronary angioplasty, or coronary
artery bypass grafting. Heart failure or congestive heart
failure and cancer (including breast cancer, colon or rectal
cancer, esophageal cancer, leukemia or lymphoma, lung
cancer, pancreatic cancer, prostate cancer, etc.) were self-
reported. Type 2 diabetes was defined as use of diabetes
medications or fasting glucose ≥ 126 mg/dl.
Genome-wide SNP array genotyping
Illumina Human Omni 2.5 v1 was used to perform
whole genome SNP genotyping on each study participant
by CIDR (www.cidr.jhmi.edu), and the resulting data
has been submitted to dbGaP under accession number
phs000397.v1.p1. Genome-wide SNP variants within tar-
geted sequenced regions were used as controls for sequen-
cing accuracy as described below.
Pooled sequencing and indexed custom library
preparation
We have previously published the entire protocol for
custom hybridization capture of multiplexed, indexed
next generation sequencing [20, 27]. Briefly, customized
adapter, blocker, pre- and post-hybridization PCR ampli-
fication primers and all index sequences used are listed
in Additional file 1: Table S5 of the same report. We
performed pooled capture of 464 candidate genes
(Additional file 1: Table S3) selected collectively by the
LLFS investigators due to their published association
with age-related phenotypes. Candidate gene resequen-
cing was performed from individually indexed DNA
samples from LLFS participants [https://longlifefamilys-
tudy.wustl.edu/LLFS/Home.html]. The bait set was cre-
ated using the Agilent eArray online tool [https://
earray.chem.agilent.com/earray/] for the Agilent SureSe-
lect Custom DNA Capture [http://www.genomics.agi-
lent.com] using 2X tiling, an exon-centered layout
strategy, and eliminating probes that overlap standard
repeat masked regions by 20 or more bases. In total,
there were 2,500,709 bases (2.5 Mb) covered by baits in
6,966 distinct intervals.
Sequencing
Sequencing was performed in the Genome Technology
Access Center at Washington University using the HiSeq
2000 platform, generating 101 bp paired-end reads.
GWA and sequencing information for the LLFS partici-
pants is available in dbGaP using accession number
phs000397.v1.p1.
Sequencing alignment, variant calling and filtering
Sequencing analysis for indexed captures of all LLFS
participants followed previously reported methods (27;
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section entitled “Pooled indexed custom capture data
analysis” for more details). Briefly, raw sequence data
was aligned against the human genome (hg19/NCBI
37.0) using Novoalign (Novocraft, Inc.) and, from
aligned reads, variants were called using samtools-0.1.18
mpileup at only the 2.5 Mb of target sequence within
our custom hybridization array.
The thresholds used for filtering called variants from se-
quencing data were determined by comparing common
base positions shared with existing GWA data. For gene-
level burden tests, variants were filtered for coverage <5-
fold, quality score <45, call rate < 60 %, MAF> 0.01, Mendel
errors, and nonfunctional variants. Single variants were fil-
tered for coverage <5-fold, quality score <45, call rate <
60 %, and Mendel errors. For rare variants (<2 % minor
allele frequency), these thresholds provided a sensitivity
of ≥94.9 % and specificity of ≥99.9 % [27]. Mendel error
cutoffs were implemented as follows: MAF = 0 to <0.01
for >2 pedigrees with the Mendel error; MAF= 0.01 to <0.05
for ≥7 pedigrees; MAF = 0.05 to <0.1 for ≥12 pedigrees;
MAF = 0.1 to <0.2 for ≥26 pedigrees; MAF = 0.2 to <0.3
for ≥30 pedigrees; MAF = 0.3 to <0.4 for ≥32 pedigrees;
MAF = 0.4 to <0.51 for ≥38 pedigrees.
Statistical analyses
Trait exceptionality scores for survival, BMI, blood pressure,
blood lipid levels, blood glucose level, blood insulin level,
cognitive function, type 2 diabetes, heart disease, cancer,
and stroke
The LLFS cohort is enriched with longer-lived and
healthier individuals than the general population, as well
as the Framingham Heart Study. To account for this dif-
ference and increase our statistical power for detecting
sequence variants associated with aging-related pheno-
types, such as survival, BMI, blood pressure, blood lipid
levels, blood glucose level, blood insulin level, cognitive
function, type 2 diabetes, heart disease, cancer, and
stroke are transformed to “trait exceptionality scores”.
Higher trait exceptionality scores indicate that, for a
given trait, an individual is significantly different from
the reference population for the same trait, resulting in
longer individual survival and/or better health. Using
sex- and birth-year specific cohort life tables from the
2012 trustees report of the United States Social Security
Administration, the trait exceptionality scores for sur-
vival were calculated for the oldest (proband) generation
in LLFS, along with any blood relatives within the same
generation regardless of age. These calculations are con-
ditional on survival to age 40 and were determined as
the negative logarithm of the probability of survival be-
yond age at last contact. Trait exceptionality scores for
BMI, blood pressure, blood lipid levels, blood glucose
level, blood insulin level, and cognitive function were
also calculated as the negative logarithm of the
probability of the trait score compared to the age/sex/
birth-cohort matched in the Framingham Heart Study.
Trait exceptionality scores for type 2 diabetes, heart dis-
ease, cancer, and stroke were calculated as the negative
logarithm of the probability of the onset age of the dis-
ease, and compared to the distribution of the age of on-
set for each trait in the Framingham Heart Study. There
are two additional components to the HAI, which are
pulmonary vital capacity and serum creatinine. However,
these were not available in Framingham Heart Study and
were not included in our analyses.
Phenotype transformation and covariates adjustment
To increase the power and reduce the confounder ef-
fects of our analyses, we performed the following covari-
ates adjustment and transformation. HbA1c was adjusted
for age, age2, age3, field center and the top twenty princi-
pal components (PCs); the standardized residuals from a
stepwise covariate adjustment were used as final pheno-
type for the following association analyses. The
leukocyte telomere length was transformed using an in-
verse normal function. This transformed trait was ad-
justed for covariates age, sex, education, field center,
smoking, alcohol consumption, marital status, history of
heart disease, and twenty PCs (PC8 was the only signifi-
cant PC associated with leukocyte telomere length in the
multivariate polygenic model). Mortality weighted
healthy aging index were adjusted for age, sex, and 10
PCs and the residuals were used in the following ana-
lyses. The residuals of trait exceptionality scores adjusted
for field centers and 20 PCs were used in the following
analyses.
Single variant association testing
Family relatedness was estimated based on pedigree
structure using the “kinship” R package. Accounting for
this relatedness within families as random effects, the
additive genetic fixed effects of SNPs were analyzed
using the linear mixed effects model implemented in the
“lmekin” R packages [21, 22]. Q-Q plots for the pheno-
types analyzed are shown in Additional file 1: Figure S1
and demonstrate that, compared to genomic control
(calculated as median of observed p value / median of
expected p value to avoid estimation bias), each is within
0.578–1.09 using this approach. Thus, the type I error
rate is low in this study.
Rare variant testing across genes
Currently un-weighted sum score (UWSS) [23],
weighted sum score (WSS) [24], P-value Weighted Sum
Test (PWST) method [25] and family based sequence
kernel association test (famSKAT) [26] are commonly
used for estimating the effects of rare variants. Because
the PWST and famSKAT are likely to have greater power
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to detect rare causal variants, we applied these two algo-
rithms to assess the influence of called rare variants.
This was necessary since standard association tests of in-
dividual rare variants (MAF < 0.01) are underpowered
unless sample sizes or effect sizes are very large, func-
tional variants within the same gene based on bioinfor-
matics annotation by ANNOVAR [27] were analyzed
together in this study. For each group of variants, UWSS
was calculated as the total number of variant alleles car-
ried by a subject. The weight was calculated based on al-
lele frequency in controls and WSS was calculated as the
weighted sum of minor alleles over a group of variants.
The UWSS or WSS score was treated as a single pre-
dictor variable (X) and fit into a linear model. The kin-
ship matrix was incorporated into the linear models to
adjust for familial relatedness between subjects. Parame-
ters in each model were estimated by the maximum like-
lihood algorithm and tested by the Wald test. Rather
than using a fixed weight, the PWST method adaptively
calculates the weights for individual variants from the
observed genotype and phenotype data and then per-
forms a permutation procedure for family data to avoid
false positive inflation due to the over fitting of the adap-
tive score WSS.
Results
Sample characteristics
Phenotype
Our results included 4,217 LLFS subjects (mean of age
70.56 for men and 70.05 for women) with complete
phenotypic and genotypic information. Individuals with
inadequate GWA or sequencing coverage were excluded.
The study participants tend to have healthier profiles
compared with other cohorts of adults. For these indi-
viduals, the mean score of healthy aging index (3.64 in
men and women) and mortality weighted healthy aging
index (3.24 in men and 3.03 in women) are low. The
average age of the LLFS probands and their relatives
(95.8 in men and 99.4 in women) is much higher than
the cohort life expectancy of US and Danish (an LLFS
study site) early 20th century birth cohorts (60–70 years)
and the current life expectancy in both populations
(~80 years).
Sequencing results
To reduce false positive variant calls, stringent filtering
of raw sequence data was employed and is described in
Table 1. After filtering, 30,112 variants within 439 genes
were identified with an average coverage of 47-fold,
quality score of 175 and call rate of 0.97. As shown in
Fig. 1, 37.4 % (11,261) of all called variants fell within
coding regions with 22.4 % (6,745) being either missense
(non-synonymous SNV) or nonsense (stop-gain and
stop-loss) variants; 50.7 % (15,281) fell within regulatory
5’ or 3’ untranslated regions (UTR5 or UTR3, respect-
ively). The majority of variants (59.8 %) were found
within a single LLFS family (Additional file 1: Table S4)
and (88.74 %, n = 26,723) were rare, occurring at <1 % in
the general population, and 12,303 (46.04 %) were sin-
gletons (Additional file 1: Table S5).
Single variant analyses
Because there are correlations between the target pheno-
types, the likelihood of a single variant having a func-
tional effect on a given phenotype was Bonferroni
corrected by dividing 0.05 by the total number of vari-
ants queried without accounting for the number of ana-
lyzed phenotypes. This resulted in p-values of 7.56x10−6
for survival and cancer and 1.47x10−5 for HDL, LDL and
triglycerides. We first attempted to determine if any sin-
gle variant identified by sequencing was significantly as-
sociated with survival. We identified a novel regulatory
variant in the 3’ UTR of Oligonucleotide/Oligosacchar-
ide-Binding Fold Containing 1, located on chromosome
10q24.33 (OBFC1; see Table 2) found in 13 individuals
from six pedigrees (Additional file 1: Table S6), which
was significantly associated (p = 6.18x10−7) with trait ex-
ceptionality for survival in long lived families. Intronic
variants of OBFC1 genotyped by Illumina array were
also queried, and two rare variants (rs79250842 in 11 in-
dividuals from 5 pedigrees and rs77987791 in 5 individ-
uals from 1 pedigree) were also found to have a
significant association with survival (Fig. 2). OBFC1 is
involved in telomere maintenance and falls within a re-
cently reported LLFS family-based association peak for
telomere length on chromosome 10 as shown in Fig. 2
[16]. This observation is supported by the association of
the same OBFC1 intronic variant (rs77987791) with
telomere length (p = 0.038). Interestingly, one long-lived
pedigree (pedID 25609942) with 14 family members was
clustered for all three rare variants in seven family mem-
bers, which suggests that multiple rare variants within
OBFC1 might contribute to longer lifespan. The com-
parison of “survival” to OBFC1 genotype is shown in
Additional file 1: Figure S2A.
Linear mixed model based single variant testing is not
a stable method for rare variants with <10 minor allele
Table 1 Filter Applied in LLFS sequence data
Among 464 Candidate genes, 448 genes with 48,918 variants
sequenced
Filter 1: ≥ 5x coverage 47 ± 36
Filter 2: ≥ 45 quality score 175 ± 53
Filter 3: ≥ 60 % call rate 97 % ± 7 %
Filter 4: Mendel Errors MAF dependent
439 genes with 30,112 variants analyzed
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copies [28], which is strengthened by our pedigree-based
structure. While the effect of any single variant may be
slight, we found a significant association with survival
for 23 different variants in 23 healthy aging candidate
genes (Table 3). Among these 23 variants, only four have
been described in dbSNP. Eight of these genes (in bold)
have published reports linking them to longer lifespan
[9, 29–34]. These variants clustered in two families with
longer survival (Fig. 3), suggesting that the aggregation
of multiple variants in these genes may have a larger ef-
fect on survival. One subject who survived to age 110
carried 15 of these variants, and another surviving to age
101 years carries 9 of these variants. None of the vari-
ants were carried by spousal controls.
Among the 439 candidate genes, 160 are well-known
human longevity related genes based on LongevityMap
(http://genomics.senescence.info/longevity/) [35] and A
Catalog of Published Genome-Wide Association Studies
(http:/www.genome.gov/gwastudies/). When considering
survival and any single variant with a p-value of <0.05
and more than 10 allelic copies in the LLFS cohort, we
replicated 76 variants within these 160 genes (Additional
file 1: Table S7), which supports the validity of our ana-
lysis model. Four variants within FOXO3, a well-known
longevity related gene [36–39], were replicated for an as-
sociation (p < 0.05) with survival.
We found associations with phenotypes other than sur-
vival. One candidate gene, IGF1R (Insulin-Like Growth
Fig. 1 The distribution of sequenced variants within different genomic region
Table 2 Significant results of single variant testing for variants with more than 10 copies. Nine single variants with at least 10 allelic
copies were identified within five phenotypes. There were 6,613 variants analyzed across 426 genes for survival and cancer and
3,389 variants analyzed across 408 genes for HDL, LDL and triglycerides
Phenotype (TE Score) chr Position (hg19) rsID gene Function Ref Variant MAF N Beta SE P-value
Survival 10 105642272 OBFC1 UTR3 C G 0.002 810 3.58 0.71 6.2E-7
Cancer 15 99501295 IGF1R UTR3 A G 0.007 4210 0.58 0.13 3.7E-6
HDL Cholesterol 16 57005301 rs1532625 CETP intron T C 0.38 3053 0.19 0.03 2.4E-13
16 57015091 rs5880 CETP nsyn-exon C G 0.047 4049 −0.32 0.06 1.2E-8
16 57017319 rs1800777 CETP nsyn-exon A G 0.029 3982 −0.40 0.07 8.1E-9
LDL Cholesterol 6 152679594 rs62426382 SYNE1 syn-exon G A 0.016 4035 0.45 0.09 1.6E-6
19 45396144 rs11556505 TOMM40 syn-exon T C 0.10 4018 −0.19 0.04 1.5E-6
19 45397229 rs1160983 TOMM40 syn-exon A G 0.02 2686 0.53 0.10 1.2E-7
Triglyceride 11 116703640 rs5128 APOC3 UTR3 G C 0.09 4003 −0.21 0.04 1.2E-7
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Factor 1 Receptor, located on chromosome 15q26.3) is
well known to be associated with cell growth and various
cancers [40]. As shown in Table 1, we noted one new
cancer associated rare UTR3 variant (chr15:99501295)
in this gene.
In addition, four genes (CETP, APOC3, SYNE1 and
TOMM40) were associated with blood lipid levels. The
cholesterol ester transfer protein, CETP (located on
chromosome 16q21), is essential for metabolism of plasma
lipoproteins [41]. Three known HDL cholesterol related
variants within CETP, one common intronic variant
(rs1532625) [42] and two rare exonic variants (rs5880,
rs1800777) [43], were replicated in our study. APOC3
(Apolipoprotein C3, located on chromosome 11q23.3) is
critical for triglyceride metabolism and a potential
therapeutic target for metabolic syndrome [44]. One
known common triglyceride related variant (rs5128)
[45] in the UTR3 region of APOC3 was replicated.
LDL cholesterol was associated with one synonymous
variant in SYNE1 (Spectrin Repeat Containing,
Nuclear Envelope 1, on chromosome 6q25.2) and two
synonymous variants in TOMM40 (Translocase Of
Outer Mitochondrial Membrane 40 Homolog, on
chromosome 19q13.32). TOMM40 has been identified
in genome-wide screens for dyslipidemia and carotid
artery disease [46, 47]. More importantly, TOMM40
rs10524523 polymorphism in combination with APOE
alleles significantly influences late-onset Alzheimer’s
disease and longevity [48]. Comparisons for all variants
listed in Table 2 between their associated phenotype and
the variant genotype are shown in Additional file 1: Figure
S2A-I.
Analyses of multiple variants across genes
To better characterize genes associated with our pheno-
types due to multiple, pedigree-specific rare variants ra-
ther than more common single variants, we aggregated
rare functional variants (exonic, UTR3, UTR5, splicing
and non-coding RNA) within the same gene using the
PWST [25] and famSKAT [26]. For association results,
Bonferroni correction of 0.05 divided by the total num-
ber of genes resulted in a p < 1.14x10−4 for significance
and p < 1.0x10−3 would merely be suggestive. With re-
spect to survival, none of the candidate genes passed this
significance threshold. When comparing our association
results for survival to published longevity related genes,
20 genes were replicated with p-value <0.05 (Additional
file 1: Table S8).
We next performed PWSK and famSKAT analyses on
our candidate genes to see if any gene harbored mul-
tiple putatively functional variants associated with the
individual Healthy Aging Index (HAI) and those results
are listed in Table 4. GSK3B (glycogen synthase kinase
3 beta, on chromosome 3q13.33) achieved significance
by PWSK. GSK3B, a serine-threonine kinase, has been
associated with Alzheimer’s disease [49, 50] and may
Fig. 2 Variant-wise association results on chromosome 10 around OBFC1 for telomere length phenotype (gray) and exceptional survival score
(green) on chromosome 10 using both 1000 Genomes Project hybrid and candidate gene sequenced genotypes. Two additional rare variants
from genome-wide array results showed significant association with survival exceptionality score. The association p-value of rs77987791 with
telomere length is 0.038
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regulate human aging via negative regulation of glucose
homeostasis and Wnt signaling. In addition, NOTCH1
was significantly associated with diastolic blood pres-
sure and TP53 with HDL (Table 4). NOTCH1 (chromo-
some 9q34.3) is involved in a variety of developmental
processes by controlling cell fate. In mice, NOTCH1
signaling is also required for vascular development
[51]. TP53 (tumor protein P53, located on chromosome
17p13.1), is a well known tumor suppressor that
regulates cell cycle and DNA repair. An inverse correl-
ation of HDL cholesterol with cancer risk [52] might
be explained by the association of TP53 with HDL
cholesterol.
These results are likely an underestimate of significant
or suggestive variants. Unfortunately, non-uniform
hybridization to target loci due to local sequence context
and the need for stringent filtering to reduce false posi-
tives resulted in gaps within the covered coding se-
quence of most genes, which could affect results due to
false negatives. This is why the well-known longevity
gene, ApoE [53], was not included in our analyses.
Discussion
The mechanisms driving healthy human aging are still
mostly unclear. There is much debate on the evolution-
ary versus adaptive mechanisms of aging, such as pro-
grammed longevity, hormonal regulation of aging by
insulin/IGF-1 signaling, programmed decline of the im-
mune system, wear and tear theory, rate of oxygen basal
metabolism, cross-linking theory and free radicals the-
ory. These mechanisms are not inherently mutually
exclusive and it is likely that aging is dictated by combina-
tions of multiple mechanisms. Regardless, Kirkwood and
Melev stated in a recent review that “it is obvious…that
duration of life is dependent upon genotype” [54].
To take advantage of the unique family structure of
the LLFS cohort, we have performed candidate gene
resequencing to identify familial sequence variation that
could explain multiple exceptional phenotypes contrib-
uting to long lifespan and healthy aging. Our results are
limited by gaps in sequencing coverage of some genes
due to non-uniform hybridization of baits across the en-
tire cohort, which may mean an underestimate in the
Table 3 Significant results of single variant testing for variants with less than 10 copies. Twenty-three rare variants with less than
10 minor allele copies were identified for a single phenotype (longevity). These variants clustered in two families with high trait
exceptionality scores for longevity. Genes in bold have a previously published relationship to longevity [9, 29–34]
chr Position (hg19) rsID gene Function Ref Variant Minor Allele Count MAF N Beta SE P-value
7 17385235 AHR UTR3 A G 5 0.0006 810 3.58 0.71 6.18E-07
11 27680107 rs8192466 BDNF nsyn-exonic A G 8 0.0009 810 5.02 1.01 7.41E-07
16 57015065 CETP intronic T C 3 0.0004 809 5.00 1.01 8.69E-07
1 207813049 CR1 UTR3 A G 5 0.0006 810 5.02 1.01 7.41E-07
8 6735377 DEFB1 nsyn-exonic T C 1 0.0001 809 5.03 1.01 7.22E-07
10 71139772 HK1 nsyn-exonic T C 1 0.0001 794 5.04 1.01 6.53E-07
1 209959231 IRF6 UTR3 G A 4 0.0005 810 3.58 0.71 6.18E-07
21 35195906 ITSN1 syn-exonic A C 1 0.0001 810 5.02 1.01 7.41E-07
15 100256347 MEF2A UTR3 C T 2 0.0002 810 5.02 1.01 7.41E-07
1 12073445 MFN2 UTR3 T C 3 0.0003 810 5.07 1.01 6.10E-07
4 100544175 MTTP UTR3 G A 1 0.0001 810 5.07 1.01 6.10E-07
2 1794502 MYT1L UTR3 T C 1 0.0001 810 5.02 1.01 7.41E-07
16 50267300 PAPD5 UTR3 T C 4 0.0005 810 3.58 0.71 6.18E-07
2 223158616 PAX3 UTR3 T C 3 0.0003 810 3.58 0.71 6.18E-07
7 95214257 PDK4 UTR3 G A 2 0.0002 810 5.07 1.01 6.10E-07
5 149206403 rs374853976 PPARGC1B syn-exonic A G 1 0.0001 714 5.07 1.00 4.72E-07
10 99130549 RRP12 nsyn-exonic T C 1 0.0001 780 5.02 1.01 7.66E-07
17 28525015 rs199875985 SLC6A4 UTR3 G A 1 0.0001 810 5.07 1.01 6.10E-07
15 67479818 rs144245324 SMAD3 syn-exonic T C 3 0.0004 767 5.02 1.02 9.22E-07
3 24163883 THRB UTR3 T C 7 0.0008 810 3.58 0.71 6.18E-07
14 81610971 TSHR UTR3 A G 2 0.0002 810 5.07 1.01 6.10E-07
21 46189291 UBE2G2 UTR3 T C 3 0.0004 810 5.02 1.01 7.41E-07
19 9770038 ZNF562 intronic T G 2 0.0002 810 3.58 0.71 6.18E-07
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number of familial variants in these genes. This strategy
was previously used to identify rare familial variants in
VEGFC (Vascular Endothelial Growth Factor C) by using
linkage information in families with high LOD scores to
inform targeted resequencing for rare variants. This
experiment identified a familial variant in VEGFC that
explained 23.8 % of phenotypic variance within a pedi-
gree, but the same variant only described 0.1 % of the
phenotypic variance in unrelated individuals [55]. The
same strategy was employed in the Insulin Resistance
Fig. 3 Twenty-four rare variants within twenty-four genes clustered in two long-lived LLFS families (a) pedID 25609942 and (b) pedID 38652533.
Individual 2418 and 4441 lived to 110 and 101 years of age, respectively. The longevity-associated genes harboring rare variants within these
individuals (and their offspring) are listed below their symbol
Table 4 Collapsed rare variant analysis of candidate genes associated with HAI. These genes were found to have a p-value <1.0x10−3 by
at least one burden-testing algorithm
Phenotype Gene RefSeq Total Exons Analyzed Exons Indiv Seq (#) Variants called (#) Ped (#) P-value (PWST) P-value (Skat)
Healthy Aging Index
(Mortality Weighted)
GSK3B NM_002093 12 8 3217 77 121 1.00E-4 2.08E-4
Diastolic Blood Pressure NOTCH1 NM_017617 34 3 4112 55 78 1.00E-4 5.37E-3
HDL Cholesterol TP53 NM_000546 11 6 4073 21 86 1.00E-4 8.05E-3
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Atherosclerosis Family Study to identify a rare variant
within the ADIPOQ (Adiponectin, C1Q And Collagen
Domain Containing) gene describing 63 % of the vari-
ance of plasma adiponectin levels, which are critical for
glucose homeostasis [56]. Our results validate multiple
SNPs and genes (OBFC1, CTEP, ZNF562) found associ-
ated with longevity and healthy survival. Using a
sequencing-based approach to identify rare variants
within pedigrees associated with exceptional pheno-
types. Of note, we identified one rare, novel variant in
OBFC1 as well as two intronic variants from LLFS array
data associated with survival. OBFC1 is involved in
telomere maintenance; its role in promoting exception-
ally healthy aging is intriguing given that this gene re-
sides squarely within a family-based association peak
for telomere length recently reported from the same
LLFS families [16]. The idea that many longevity-
associated variants can presumably work in synergy
with an additive beneficial effect is supported by the
observations from three LLFS families. One exception-
ally long-lived LLFS family carries all three OBFC1
variants, while 23 additional beneficial rare variants are
clustered in two other exceptionally long-lived LLFS
families.
Because effect sizes from single rare variants are typ-
ically small, collapsing rare variants across larger loci
(e.g. genes or pathways) can aggregate variants and
highlight the importance of a larger genetic locus [25].
By analyzing our sequencing results in this fashion, we
identified a more diverse set of genes associated (or
suggestive of association) with additional healthy aging
phenotypes. GSK3B, which is a kinase for over forty
different proteins and plays key roles in numerous
intracellular signaling pathways (cellular proliferation,
migration, inflammation and immune response, glu-
cose regulation, and apoptosis) [57] was identified in
this analysis and may play an important role in healthy
aging. This gene has been associated with a number of
age-related diseases such as type II diabetes, Alzheimer’s
disease, inflammatory disorders, cancer and bipolar dis-
order [58].
Another healthy aging candidate gene, CETP, is a well-
known regulator of HDL and has been associated with
healthy aging in Ashkenazi Jewish [59, 60] as well as
Alzheimer’s disease [61]. The negative association of sev-
eral variants with HDL, LDL and triglycerides in our
study indicates that harmful genetic variants still exist in
the long-lived subjects. This paradoxical phenomenon
might be due to antagonistic effects on the development
of other age-related disorders, gene-age, gene-gene, or
gene-environment interactions [62]. To understand
these intersections, further investigation of age and en-
vironment specific effects of these lipid regulatory genes
on multiple aging phenotypes is needed.
Conclusions
Under the Rare Variant/Complex Phenotype hypothesis,
multiple rare variants have an aggregate effect on com-
plex phenotypes or diseases, but identifying the genes
and the relative contributions of the various sequence
changes is difficult. By leveraging the pedigree structure
and cohort size of the LLFS study, we demonstrate the
utility of sequencing within pedigrees to identify inher-
ited genetic variation influencing specific parameters of
healthy aging. These data are limited by representing
primarily genes that were already known to be associ-
ated with the various phenotypes being investigated. A
larger survey of the genome in the LLFS cohort, espe-
cially the linkage peaks for multiple healthy aging phe-
notypes, will facilitate discovery of new genes and
putative mechanisms for the genetic regulation of the
complexities of aging.
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